{
  "abstract": "Background: Transcatheter aortic valve replacement (TAVR), a standard therapy for aortic stenosis, is preferred for older or high-risk patients. Various complications, including heart failure (HF), resulting in increased mortality, have been reported in the literature. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended in HF, irrespective of ejection fraction; however, their role in reducing post-TAVR cardiovascular complications remains underexplored. We conducted a retrospective study to evaluate cardiovascular outcomes associated with the use of SGLT2i in post-TAVR patients.\n\nMethods: This retrospective cohort was based on a global database of electronic health records of more than 160 million patients. After propensity-score matching, the study population included 9930 post-TAVR diabetic patients divided into 2 cohorts based on their exposure to SGLT2i. Exposure to SGLT2i was defined as exposure after 1 day of TAVR.\n\nResults: In this study of 9930 post-TAVR diabetic patients, the primary outcome of major adverse cardiovascular events and secondary outcomes, ie, cardiovascular mortality, ischemic stroke, and HF exacerbation, were significantly reduced in SGLT2i-exposed post-TAVR patients at the 1-month and 1-year follow-up. Hemorrhagic stroke was comparable at the 1-month follow-up; however, it was significantly lower in SGLT2i-exposed cohorts at the 1-year follow-up. The risk of new-onset myocardial infarction was significantly reduced at 1 month; however, it was comparable between the 2 cohorts at the 1-year follow-up. Our study also demonstrated a significant reduction in the risk of end-stage renal disease in the SGLT2i-exposed cohort at the 1-year follow-up. The periprocedural risk of acute kidney injury (within 7 days of TAVR) as well as at the 1-month and 1-year follow-up was significantly lower in the SGLT2i-exposed cohort.\n\nConclusions: In this study, post-TAVR SGLT2i use in diabetic patients was associated with reduced cardiovascular morbidity and mortality for up to 1 year.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medicine, SUNY Upstate Medical University, Syracuse, New York"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Muhammad Hanif"
    },
    {
      "affs": [
        0
      ],
      "name": "Waasay H. Khan"
    },
    {
      "affs": [
        0
      ],
      "name": "Shiva P. Sah"
    },
    {
      "affs": [
        0
      ],
      "name": "Jai S. Nagarajan"
    },
    {
      "affs": [
        0
      ],
      "name": "Jenish Bhandari"
    },
    {
      "affs": [
        0
      ],
      "name": "Stephen J. Knohl"
    },
    {
      "affs": [
        0
      ],
      "name": "Cynthia C. Taub"
    },
    {
      "affs": [
        0
      ],
      "name": "Andrew M. Weinberg"
    },
    {
      "affs": [
        0
      ],
      "name": "Ankur Kalra"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a7hytxyfmth0t.bib",
  "cited_by": 0,
  "doi": "10.1016/j.jscai.2026.105561",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13700018/",
  "id": "a7hytxyfmth0t",
  "issns": [
    "2772-9303"
  ],
  "landing_url": "https://doi.org/10.1016/j.jscai.2026.105561",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2705|Cardiac Valve Diseases and Treatments"
    ]
  ],
  "openalex": "W7202377362",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13700018/pdf/?tool=EBI",
  "pmcid": "PMC13700018",
  "pmid": "42936081",
  "published": "2026-08-13",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/a7hytxyfmth0t.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:32Z",
      "native_id": "PMC13700018",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.jscai.2026.105561"
    },
    {
      "first_seen": "2026-10-30T12:21:51Z",
      "native_id": "PMC:PMC13700018",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13700018"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2705|Cardiac Valve Diseases and Treatments",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Clinical Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors After Transcatheter Aortic Valve Replacement in Patients With Diabetes: A Global Retrospective Study",
  "title_text": "Clinical Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors After Transcatheter Aortic Valve Replacement in Patients With Diabetes: A Global Retrospective Study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:36:30Z",
  "url": "https://research.draconitic.com/paper/a7hytxyfmth0t",
  "venue": "Journal of the Society for Cardiovascular Angiography & Interventions",
  "versions": []
}